_______
OUR NEW PROFILE IS: (Nasdaq: BCAN)
YAHOO FINANCE Has the Entire Float Under 1.2Mill!!
The EZ-G device represented a $28 million transaction
BCAN IS AN EARLY PLAYER IN THE AI-POWERED ADULT TOY MARKET
INSIDERS OWN OVER 64% OF THIS ONE!!
_____________________
Hello Everyone,
Our last profile closed just under the high of the day and we want you to keep an eye on it this upcoming week.
We have another profile with several catalysts that we want you to take a look at for Monday’s session.
Pull up BCAN immediately.
In the adult toy industry, AI and wearable sex toys have the potential to revolutionize the market, which is expected to be worth $62.32 billion by 2030. (9)
One company to keep an eye on in this space in the AI-power sex toy market is BYND Cannasoft Enterprises Inc. (BCAN).
This one has a few catalysts to look at:
Extremely Low Float: Less than 1.2M shares available in its public float according to Finviz.(5).
Huge Market: The global sexual wellness market is projected to be worth $125B by 2026 (2)with the sextech market expected to reach $62.32B by 2030 (1)
Intellectual Property: Positive news on patent applications could prove to be a significant catalyst in 2023.
Early-mover advantage: As an early mover in the AI-powered adult toy market, they have the potential to establish itself as a leading player in the industry, providing a competitive edge over later entrants. (1)
Strong Insider Ownership: Insiders own over 64% of the shares as of 3/2/2023 according to Finviz.com.(5)
______
Overall, BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) positive catalysts, such as its potential for growth and low public float, make it an attractive option for those looking to take advantage of swings with significant potential.
Maybe that’s why BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) insiders are holding onto so many shares according to Finviz. (5)
Strong insider ownership can be an indication of a company’s health and long-term potential. When insiders own a significant percentage of a company’s shares, they have a vested interest in the company’s success, which can align their interests with those of other shareholders.
High insider ownership typically signals that insiders believe in the company’s future prospects and have confidence in its management team.
BYND Cannasoft Enterprises Inc. (BCAN) has over 64% insider ownership,(5) which is a strong indication of confidence in the company’s future prospects.
This level of insider ownership could be a sign that the management team has a significant stake in the company’s success. When insiders own a large percentage of a company’s shares, it can also indicate that they are committed to the company for the long term, as they have a significant financial stake in its future performance.
The market often views high insider ownership as a positive signal, as it indicates that insiders are financially interested in the company’s success.
This can also provide shareholders with greater transparency into the company’s operations and decision-making processes, as insiders are more likely to share information with shareholders who have a vested interest in the company’s success.
VANCOUVER, British Columbia and ASHKELON, Israel, Oct. 27, 2022 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Company”) announced today its Israeli subsidiary signed an agreement with Globus Pharma LTD, a subsidiary of Israeli-based Together Pharma Ltd (TA: TGTR), for the cultivation, production, and distribution of medical cannabis products that are expected to generate significant revenues for the company before costs of manufacturing and distribution fees. The manufacturing of the medical cannabis products will adhere to BYND Cannasoft’s instructions and stringent standards. These products will be exclusively marketed and distributed by BYND Cannasoft in Israel through Globus Pharma. Due to their safety profile and strong therapeutic efficacy, the products are based on strains developed by Together Pharma and selected exclusively by BYND Cannasoft.
BYND Cannasoft’s agreement with Together Pharma will take effect upon the issuance of a full license by the Medical Cannabis Unit at the Ministry of Health of the State of Israel (the “MCU”). While BYND Cannasoft has received initial approval from the MCU to engage in medical cannabis without direct contact with the substance, there is no guarantee that it will receive a full license.
Israel has emerged as one of the leading countries for the consumption of medical cannabis in the world. According to Israel’s Health Ministry, more than 100,000 Israeli citizens have medical cannabis permits, a 1,600 percent increase over the past decade. Regulations governing the research, cultivation, processing, distribution, and sale of cannabis remain extremely strict. Israel’s Health Ministry estimated that medical cannabis consumption increased to 43 metric tons in 2021, from 28.5 million in 2020. According to Prohibition Partners, an industry analysis firm, Israel’s medicinal cannabis market had an approximate value of $264 million in 2021, roughly $7 million less than all of Europe’s.
Yftah Ben Yaackov, CEO and Director of BYND, said, “The medical cannabis arena is being commercialized rapidly in Israel, and we expect to see more development in Israel and worldwide. Many of today’s decision-makers in the pharmaceutical industry and the medical community understand the benefits produced by specific cannabis strains.” Mr. Yaackov continued, “The products BYND Cannasoft plans to bring to market may provide additional treatment options and respond to the unmet medical needs of patients. After an in-depth and lengthy review, we partnered with Together Pharma because we knew we could have a tremendous impact on the community. The high-quality medical cannabis Together Pharma produces in accordance with BYND Cannasoft’s high quality and safety standards – will help us realize our goal of improving patients’ lives.”
This system gives the growers a deep insight into all aspects of managing a cann-a-bis farm and cann-a-bis distribution from the amounts of fertilizer right to managing delivery revenue – all with a few clicks. The company’s powerful BI tools allow growers to receive information in real-time, in great resolution to allow optimal efficiency and profit.
The Company’s plans include the construction of 4 state of the art greenhouses, housing approximately 2.5 acres of total growing area.
BYND Cannasoft Enterprises Inc. estimates that once fully operational, its Cann-a-bis farm facility will be able to produce 7,500kg of raw cann-a-bis each year.
BYND also intends to work with strategic partners to develop and market new, proprietary cann-a-bis infused products for sale throughout Israel and for export.
The company operates on 3 parallel levels as part of its plans to enter the market for growing and selling medical cann-a-bis:
- The company is working to transfer the initial permit for the cultivation and multiplication of medical cann-a-bis according to the partnership agreement with the Bzizinsky family, after its transfer, the company will operate for the planning and construction of a growing facility in Moshav Kochav Michael.
- The company has completed the planning and placement of an internal breeding facility and has applied for a growing and breeding license for this facility.
- The company has submitted an application for a license to trade in medical cann-a-bis “without contact with the substance” known as a constructive license, after receiving it the company will be able to implement agreements it has signed with various growers for marketing and sales of the company’s private label.
BCAN broke the news in September that they have signed a share purchase agreement to acquire 100% ownership of Zigi Carmel Initiatives & Investments Ltd. (ZC) which holds the patent pending intellectual property for the EZ-G device. Under the terms of the share purchase agreement, BCAN will issue to ZC’s owner 7,920,000 common shares and pay $100K to cover legal expenses.
The EZ-G device represented a $28 million transaction that Ben Yaackov says will add value to BYND as it seeks regulatory approval and patent registration.
The EZ-G device uses proprietary software (provisional application) to regulate the flow of low-concentration CBD oils into the soft tissues of the female reproductive system to treat candida, dryness, scars and other health issues.
“This, together with our great development in the software field and the preparations of obtaining the license to practice medical cannabis, makes the last two years a period of great prosperity and success,” he adds. “We are confident that it will bring significant value for the Company in the upcoming year.”
Wrapping up 2022 and moving into 2023, Ben Yaackov says he expects to see continued progress in the Company’s software development and sales expansion. Additionally, BYND is in the final stage of obtaining a license to engage in the sale of medical cannabis without connecting with the substance.
“This is a special license that few have in Israel. It allows you to establish products in the medical cannabis field, a label of your own, through an existing grower that has the license to grow medical cannabis in Israel,” he explains. “That will bring us another revenue from the side of selling medical cannabis products, and above all that, I believe that we will significantly advance the new project and finish the patent registration and put other necessary regulations and build a prototype until the end of the fourth quarter of 2023.”
CLIENTS
BYND Cannasoft Enterprises Inc. Signs Agreement for the Acquisition of Israeli-Based Zigi Carmel Initiatives & Investments Ltd. In a Share Swap Agreement Valued at US $28Mn
VANCOUVER, British Columbia, Sept. 18, 2022 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) (CSE: BYND) (“BYND” or the “Company”) announced today that it has signed a share purchase agreement to acquire 100% ownership of Zigi Carmel Initiatives & Investments Ltd. (“ZC”) which holds the patent pending intellectual property for a therapeutic device (the “EZ-G device”) that uses low concentrations of CB oils, such as hemp seed oil and other natural oils, to treat certain women’s health issues…
The EZ-G device is a unique, patent-pending device that, combined with proprietary software (provisional application), regulates the flow of low-concentration CB oils into the soft tissues of the female reproductive system. According to research conducted across the globe, treatment with low-concentration CB oils can relieve candida, dryness, scars, and many other female health issues.
BYND intends to pursue the final registration of the patent and establish a marketing and sales system for the EZ-G device.The Company’s ‘Go to Market’ strategic plan is based on combined B2B and B2C sales. Numerous studies have shown CB interacts with the endocann-a-binoid system, a master regulatory system with receptors all around the body. By activating these receptors, CB can have health benefits that help make sex more approachable and pleasurable by reducing stress, enhancing one’s mood, promoting body comfort, and treating vaginal issues. According to the Brightfield Group, a cann-a-bis industry data research firm, sales of CB products could reach $11Bn by 2027. A recent Zion Market Research study indicates the market size of global gynecology devices was worth $10.8Bn in 2021 and is estimated to exceed $19.5Bn by 2028 with a compound annual growth rate (CAGR) of approximately 10.3 percent.
…
Yftah Ben Yaackov, CEO and a Director of BYND, said, “From the moment we complete the purchase of ZC, we plan to hit the ground running by initially securing any required regulatory approval from the appropriate authorities. We will continue to pursue the registration of the patent, which contains over 100 claims, prototype production and start validation tests, and contract with suppliers for the production of the device and the oils used in the EZ-G device.
The demand for a unique device combined with software, such as the EZ-G device, stems from the increasing occurrence of chronic conditions and the rising adoption of self-health management. Using a device at home is a very cost-effective treatment, and it opens up a vast channel for millions of women.” Mr. Ben Yaackov continued, “We hope to use the knowledge we have gained in the medical cann-a-bis field to significantly improve the quality of life of women suffering from symptoms such as those mentioned above.”
BYND Cannasoft Enterprises Inc. Launches Beta Test for Managing Farms CRM Platform at Israel’s Weizmann Institute of Science
VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) (CSE: BYND) (“BYND” or the “Company”) announced that its subsidiary BYND – Beyond Solutions Ltd. has signed an agreement with the Weizmann Institute of Science for the use of its proprietary software. …
Yftah Ben Yaackov, CEO and a Director of BYND, said, “This is an extremely important step in the development of BYND Cannasoft Enterprises medical cann-a-bis software since the Weizmann Institute has many greenhouses of various types that can cover all the development possibilities of the software in the coming year…”
MANAGEMENT
Moti Maram
President and Director
In 1986, together with a partner company, he founded a computer company that mainly provided services to EXATEC-compliant IBM AS 400 computers and subsequently sales and service to the first PCs in the world. After identifying a need for CRM and ERP software, Maram and his partner, Avner Tal, established a software company that manufactures CRM and ERP management software called BENEFIT in 2000.
Harold Wolkin
Harold is a retired, former Investment Banker and Financial Analyst with over 40 years of business experience. An advisor to Chief Executive Officers and Board of Directors of both public and private companies. Strong financial expertise, a Chartered Financial Analyst (CFA) and member of the Institute of Corporate Directors.
Yftah Ben Yaackov
CEO and Director
Professional lawyer since 2004. Specialized in real estate related issues on all aspects of it including real estate corporations, complex sales transactions, real estate unions, real estate taxation. Notary License holder since 2014. Managed large projects of tens of thousands Square meters for a total amount of above 400 million NIS. At the last 5 years yftah has assembled the business activity of 2 of the largest medical cannabis company’s in Israel and has an enormous experience and knowledge in this field.
Dr. Stefánia Szabó
Director
Stefánia is the Vice President of Pace Law Firm and Director of International Relations at Pace Global Advantage in Toronto, Canada. She is a former diplomat, a charismatic government services, management and public relations professional with 25 years of progressive experience. She is an international lawyer by profession, and serves as member of the executive committee of the Canada-Israel Chamber of Commerce.
Avner Tal
VP Sales & Marketing, CTO and Director
Technology director of Beyond Solution Company. I studied electronics and control. I served in the Navy and I was in the team that implemented and developed the technology and even carried out the experiments that included “smart” missiles. Joined Moti to established a computer company that supported Exatech computers and its innovative network.
NEWS
- GlobeNewswire•last month
Israeli Cannabis Technology Company BYND Cannasoft Enterprises Files US Provisional Patent Application and Full Scale PCT Application for Its EZ-G Device
The new full scale PCT application for the EZ-G device, comprised of a structure and one or more moving and vibrating elements, will utilize Artificial Intelligence (AI) to send data about learned sexual preferences to the cloud to heighten arousal, and intimacyASHKELON, Israel and VANCOUVER, British Columbia, Jan. 17, 2023 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Company”) announced today that in addition to the US Provisional Pate
- GlobeNewswire•3 months ago
CEO’s Letter to Shareholders
ASHKELON, Israel and VANCOUVER, British Columbia, Dec. 15, 2022 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (C.S.E.: BYND) (“BYND Cannasoft” or the “Company”) today issued a letter to shareholders from its Chief Executive Officer and Director, Yftah Ben Yaackov. Successful Nasdaq Uplisting On May 31, 2022, BYND Cannasoft was approved for trading on the Nasdaq Capital Market. This listing represents a significant milestone for BYND Cannasoft and enhances our ability to crea
- GlobeNewswire•3 months ago
$62 Billion Potential Sex Toy Market Could be Disrupted by Israeli Cannabis Technology Company BYND Cannasoft Enterprises’ PCT Patent Application
PCT patent application could potentially cover the EZ-G device as a sex toy, as well as a double-faceted condomASHKELON, Israel and VANCOUVER, British Columbia, Dec. 07, 2022 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Company”) announced today it is in the advanced stages of expanding its EZ-G device’s applications into the leisure field of sex toys. In addition to potentially treating annoying phenomena in the female reproductive sys
- GlobeNewswire•3 months ago
Israeli Cannabis Technology Company BYND Cannasoft Enterprises Inc. Files EZ-G Patent Application to Include Double Faceted Condom
ASHKELON, Israel and VANCOUVER, British Columbia, Dec. 01, 2022 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Company”) announced today the filing of a patent application for its EZ-G device to include an innovative double-faceted condom design. The double-faceted condom is designed to help treat various problems related to intimate relationships while making the sexual experience much more pleasurable for everyone involved. BYND Cannaso
- GlobeNewswire•3 months ago
$10.97 Billion Potential Global Condom Market Could Be a Key Driver of Growth for Israeli Cannabis Technology Company BYND Cannasoft Enterprises
A patent pending Double-faceted condom to enhance sexual pleasure marks BYND Cannasoft’s entry in a multi-billion-dollar marketASHKELON, Israel and VANCOUVER, British Columbia, Nov. 30, 2022 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Company”) announced today it is aiming to enter into the global condom market, which is expected to grow to USD $10.97 billion by 2030. The company intends to offer consumers a revolutionary design for se
- GlobeNewswire•3 months ago
Israeli Technology Company BYND Cannasoft Enterprises Inc. Announces Contract for Its Benefit CRM Cloud-Based Software as a Service CRM Platform
The agreement marks BYND Cannasoft’s commitment to penetrating additional markets and deepening services in consumer goods companies with its legacy CRM platformASHKELON, Israel and VANCOUVER, British Columbia, Nov. 17, 2022 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Company”) announced today that it has signed an agreement for the provision of software services with one of Israel’s leading air conditioning companies. Under the terms
- GlobeNewswire•4 months ago
494% Increase in Assets to US$33 million Israeli Cannabis Technology Company BYND Cannasoft Enterprises Inc. Poised for Growth
Strengthened balance sheet, increased gross margins, and reduced expenses provide increased focus on growth based on BYND Cannasoft’s CRM SaaS platform, medical cannabis, and EZ-G deviceASHKELON, Israel and VANCOUVER, British Columbia, Nov. 15, 2022 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Company”) announced today future plans for growth after posting a 494% increase in assets for the nine-month period ended September 30, 2022. The
- GlobeNewswire•4 months ago
Israeli Cannabis Technology Company BYND Cannasoft Enterprises Inc. Announces Third Quarter 2022 Financial Results
Company reports 494% growth in 2022 assets to $33 million USD and strengthened balance sheet while increasing gross margins and reducing lossesVANCOUVER, British Columbia, Nov. 10, 2022 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN, CSE: BYND) (“BYND” or the “Company”), has released its financial results for the nine-month period ended September 30, 2022. Full versions of BYND’s unaudited consolidated interim financial statements and management discussion and analysis for the
- GlobeNewswire•4 months ago
Israeli Cannabis Technology Company BYND Cannasoft Enterprises Provides Update on International Patent Application Process for its Revolutionary EZ-G Device
International Searching Authority under the Patent Cooperation Treaty (“PCT”) provides non-binding opinion that one of the inventions comprising the EZ-G device is novel and inventiveASHKELON, Israel and VANCOUVER, British Columbia, Nov. 03, 2022 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Company”) announced today that as part of the PCT patent application process for the EZ-G device, an International Searching Authority (“ISA”) exami
- GlobeNewswire•4 months ago
Tel Aviv Listed Together Pharma’s Subsidiary Globus Pharma Ltd and BYND Cannasoft Enterprises’ Subsidiary Sign First Commercial Agreement for Medical Cannabis Products
VANCOUVER, British Columbia and ASHKELON, Israel, Oct. 27, 2022 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Company”) announced today its Israeli subsidiary signed an agreement with Globus Pharma LTD, a subsidiary of Israeli-based Together Pharma Ltd (TA: TGTR), for the cultivation, production, and distribution of medical cannabis products that are expected to generate significant revenues for the company before costs of manufacturing